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1. Introduction 
Inarguably, the development of cell culture and the ability to grow human cells in vitro has 
revolutionized medicine and scientific research. In the nearly sixty years since the first 
successful culture of immortalized human tumor cells in the lab in 1952, new fields of 
research have emerged and new scientific industries have been launched. Without cell lines, 
medicine would not be as advanced as it is today. Modern techniques that allow for 
manipulation of cell have allowed for a more complete understanding of the of fundamental 
basics of cellular and molecular biology and the biological system as a whole. 
Different types of cell lines exist. Lines are maintained as continuous cultures, are 
established as primary cultures for transient studies, are created as explants of tumor or 
tissue samples, or cultivated from a single individual cell. Cell lines, especially cancer cell 
lines, are ubiquitous and are used for everything. By using cell lines, our understanding of 
cells and genes, how they function or malfunction, and how they interact with other cells 
has increased the pace of discovery and fundamentally changed how science is conducted. 
Cell lines have been established as a model of specific disease types. Individual cell lines 
have been derived from specific disease states and therefore possess specific characteristics 
of that disease state. Therefore, they are exceptionally useful to gain insight into normal 
physiology and how that physiology changes with onset of disease. Novel treatments and 
therapeutic strategies are investigated in cell lines in order to gain a fundamental detailed 
understanding of how a cell will react. Initial protocols are developed and tested in cell lines 
prior to use in animal models or testing in humans. This has enormous implications in 
discovery and reducing unintended side effects. 
The first breast cancer cell line was established in 1958. Today, lines modeling the varied 
types of breast cancer help to develop targeted therapy and to provide a molecular signature 
of gene expression. Cell lines of estrogen/progesterone receptor (ER/PR) positive, ER/PR 
negative, triple negative (ER/PR/Her2), normal mammary epithelium, metastatic disease, 
and more are so widely used that it is nearly impossible to identify a recent discovery that 
hasn’t used cell line models at some point during development.  
Unfortunately, significant shortcomings of the use of cell lines exist. Cell lines are a model 
system. They do not always predict the outcome in humans and therefore, do not replace 
use of whole organisms. They are grown and tested in isolation, therefore the influence of 
neighboring cells or organs is non-existent in cell culture systems. Over time, cells can 
differentiate resulting in a change in phenotype from the original culture. Cell lines can 
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become contaminated by infectious agents such as mycoplasma or even by other cell lines. 
Such contamination may not be readily detectable and can result in dramatically different 
results leading to false or irreproducible data. Some of these issues can be addressed to 
thwart the waste of reagents, money, and time. This includes testing and authenticating cell 
lines while they are actively grown and in use in the lab. Companies exist that can test for 
mycoplasma infection or DNA fingerprinting of cell lines to authenticate a particular cell 
line. Other shortcomings are merely inherent to this model system and must simply be 
identified and addressed.  
2. A brief history of cell culture 
Since the first successful establishment of a human cancer cell line in 1952, cell lines have 
been the backbone of cancer research. They have provided the understanding of systems at 
the molecular and cellular levels. Cell lines are used in the vast majority of research labs to 
understand the fundamentals of basic mechanisms as well as the translation to clinical 
settings.  
Modern tissue culture techniques were made possible through the contributions of many 
scientists across the world whose attempts to understand physiology and to establish a 
source of tissue to study lead to fundamental changes in our understanding of biology and 
medicine. Among the contributions include those of Sydney Ringer at the University 
College London, who determined the ion concentrations necessary to maintain cellular life 
and cell contractility, and ultimately created Ringers Solution. Through his seminal work in 
the 1880s, Ringer described the concentrations of calcium, potassium and sodium required 
to maintain contraction of a frog heart and began the steps towards modern day cell culture 
(Miller, 2004; Ringer, 1882, 1883). In 1885, Wilhelm Roux at the Institute of Embryology in 
Germany cultured chicken embryonic tissue in saline for several days. This was followed by 
the work of Ross Harrison at the Johns Hopkins University in 1907, who was the first to 
successfully grow nerve fibers in vitro from frog embryonic tissues. While this was the 
outgrowth of embryonic tissue, these tissue cultures were successfully maintained ex vivo 
for 1 - 3 weeks (Skloot, 2010)(Ryan, 2007b). In 1912, Alex Carrel at the Rockefeller Institute 
for Medical Research successfully cultured the first mammalian tissue, chicken heart 
fragments. He claimed to maintain beating chicken heart fragments in culture for over 34 
years and outliving him by one year (Ryan, 2007a). Although controversy as to whether 
these cultures were authentic or supplemented with fresh chicken hearts still remains 
(Skloot, 2010). This controversy may have slowed progress towards the establishment of cell 
lines in culture to some degree, it did not prevent work to create a source of material and 
model systems to allow for testing in vitro.  
It would be another 40 years before the establishment of the first continuously growing 
human cell line, however steady advances towards that goal were ongoing. Carrel, working 
with Charles Lindbergh, worked to create novel culturing techniques that included use of 
pyrex glass. This glass could be heated and sterilized to reduce, or preferably eliminate, 
bacterial contamination. This led to the creation of the D flasks in the 1930s which improved 
cell culturing conditions by reducing contamination (Ryan, 2007c).  
Tissue culture took another leap forward in 1948 when Katherine Sanford at Johns 
Hopkins was the first to culture single mammalian cells on glass plates in solution to 
produce the first continuous cell line (Earle et al., 1943; Sanford et al., 1948). Prior to this, 
tissues were attached to coverslips, inverted and grown in droplets of blood or plasma. 
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Her work set the stage for modern practices of growing cells in media on plates or flasks 
(Sanford et al., 1948).  
2.1 Establishment of the HeLa cell line and cell line production 
Indoubtedly, the most important factor to change biomedical research and our 
understanding of disease at the cellular and molecular levels was the establishment of the 
first continuously growing human cell line, the HeLa cell (Gey et al., 1952). In 1952, 
Henrietta Lacks was a patient with adenocarcinoma of the cervix treated at the Johns 
Hopkins Hospital. A portion of her tumor was used in the laboratory of George Gey at 
Johns Hopkins University and the revolution of modern biomedical research began. These 
cells were grown in roller flasks in specialized medium containing serum developed by 
Evans and Earle et al. and continued to proliferate (Evans et al., 1951). Almost 60 years later, 
these cells are still proliferating in laboratories across the globe and used to increase our 
understanding of cellular mechanisms from cell signaling, to the implications of 
weighlessness/zero gravity on cellular aging, and everything in between. The implications 
of establishing this cell line have been tremendous and is still ongoing. HeLa cells have not 
stopped growing and neither has the vast amount of knowledge gleened from them. 
In 1953, Gey demonstrated that HeLa cells could be infected with the polio virus and 
therefore were a useful tool for testing the efficacy of the polio vaccine that was under 
development. This set the stage for the mass production of cell lines for distribution and use 
worldwide. The National Science Foundation established the first production lab at the 
Tuskegee Institute in 1953 that would provide HeLa cells to scientists involved in the 
development of the polio vaccine (Brown and Henderson, 1983). The goal was to ship at 
least 10,000 cultures per week. At the peak of production, 20,000 cultures were shipped per 
week and a total of 600,000 cultures were shipped in the two years the lab was in existence 
(Brown and Henderson, 1983). This, along with the Lewis Coriell’s development of the 
laminar flow hood to reduce contamination of cell cultures and methods to freeze and 
recover cell lines (Coriell et al., 1958; McGarrity and Coriell, 1973, 1974)(Coriell and 
McGarrity, 1968; Greene et al., 1964; McAllister and Coriell, 1956; Silver et al., 1964), led to 
the establishment of cell repositories to house and distribute cells. It also led to the 
development of tumor specific cancer cell lines that created models of different types of 
human cancer and to an explosion of understanding of how cells work without the influence 
or perturbation of other cells. These models were also an ideal system to test novel 
therapeutics and treatment strategies without use of whole animals or humans. 
2.2 Culturing cells 
The terms tissue culture and cell culture are used interchangeably, but in reality they are 
two distinct entities. While both methods are derived from specific cells isolated from the 
whole organism, the cultures established are quite different and used for different endpoints 
(Freshney, 2010a). 
Tissue, or primary, cultures are established from isolated tissue or organ fragment, most 
commonly from tumor slices (McAteer and Davis, 2002). These primary cultures can be used 
either for immediate experimentation to determine how primary cells operate or to establish 
a continuous cell line. Generally, primary cultures are established through placing an organ 
explant into culture media and allowing for outgrowth of cells or by digesting the tissue 
fragment using enzymatic or mechanical digestion. By definition, these cultures are 
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transient. Primary culture refers to the period of time the primary tissue/organ fragment is 
kept in culture in vitro prior to the first passage or subculturing of cells, at which time they 
are referred to as a cell culture. This could range from days to a few weeks at most 
(MacDonald, 2002).  
Cell lines are primary cultures that have been subcultured or passaged and can be clonal, 
terminal or immortalized cells (McAteer and Davis, 2002). Clonal cell cultures are created by 
selecting a single cell that will proliferate to establish a single population. Terminal cell lines 
are able to grow in culture for a few generations before senescence occurs and the cell line 
can no longer survive in culture media. Immortalized cell lines are able to grow in culture 
forever. These immortalized cell lines can occur naturally, such as HeLa cells, or through 
transformation events, such as Epstein-Barr Virus transformation. All types of in vitro cell 
cultures are used in breast cancer research. 
3. The establishment of human breast cancer cell lines 
The first human breast cancer cell line, BT-20, was established by Lasfargues and Ozzello in 
1958 from an explant culture of a tumor slice from a 74 year old caucasian woman 
(Lasfargues and Ozzello, 1958). These cells are estrogen receptor alpha (ER) negative, 
progesterone receptor (PR) negative, Tumor Necrosis Factor alpha (TNF-α) positive, and 
epidermal growth factor receptor (EGFR) positive (Borras et al., 1997). While BT-20 is the 
oldest established breast cancer cell line, it is not the most commonly used line. By far, the 
most widely used breast cancer cell line worldwide is the MCF-7 cell line (Table 1 and 
Figure 1)(Burdall et al., 2003). Established in 1973 by Soule and colleagues at the Michigan 
Cancer Foundation, from where it derives its name, MCF-7 cells were isolated from the 
plural effusion of a 69 year old woman with metastatic disease (Soule et al., 1973). Since its 
establishment, MCF7 has become the model of ER positive breast cancer (Lacroix and 
Laclercq, 2004). Establishment of other cell lines has followed, including ones from other 
breast cancer types such as BRCA mutant, triple negative, HER2 overexpressing, and those 
derived from normal mammary epithelial cells such as MCF-10A cells (Soule et al., 1990) 
(Table 2). 
Cell line use in labs is ubiquitous and continues to increase. From 2000 - 2010, the 
publication of manuscripts using the 10 most commonly used cell lines has almost tripled 
(2.8% increase) (Figure 2). Clearly demonstrating that the importance of, need for, and use of 
breast cancer cell lines will not diminish in the near future. Evaluation of the existing lines 
indicates that most breast cancer cell lines in use are derived from metastatic cancer and not 
other breast cancer phenotypes (Borras et al., 1997). Indeed, the overall success rate of 
establishing a cell line is only 10%. Most of the cell lines that exist today have been derived 
from pleural effusion instead of from primary tumors and are primarily ER - lines (Table 2 
and reviewed in (Lacroix and Laclercq, 2004). This is surprising since ER - breast cancer is 
detected in only 20 - 30% of all primary tumors, whereas ER + tumors are detected 55-60% 
of the time (Ali and Coombes, 2000; McGuire et al., 1978). The reason for this discrepancy 
remains unknown, however it has been postulated that this could be because ER - cells are 
easier to establish in culture than ER + or that as cells are grown in culture, the epithelial like 
phenotype is lost while more mesenchymal traits are retained, therefore cells in culture 
appear to undergo a endothelial to mesenchymal transition (EMT) in vitro which is 
associated with the ER - phenotype (Lacroix and Laclercq, 2004). This suggests that culture 
systems are a model of metastatic disease that can grow in isolation and not a model the 
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wide heterogeneity of disease that is detected clinically. Although current cell lines are 
derived form only a subset of primary cancers, overall these lines are a reliable model to 
study the fundamental questions concerning cell growth, death, and the basic biology of 
breast cancer. Indeed, many advances in breast cancer biology have been made using cell 
culture systems and should not be dismissed because of these concerns.  
 
Cell line 
No of publications 
1/1/2000 to 12/31/2010
origin 
BT-20 79 breast 
MCF7 11813 pleural effusion 
MDA-MB-231 3489 pleural effusion 
MDA-MB-435 * 719 pleural effusion 
MDA-MB-468 486 pleural effusion 
SkBr3 372 pleural effusion 
T47D 1168 pleural effusion 
ZR75.1 96 ascites 
BT474 251 pleural effusion 
MCF-10A 451 subcutaneous mastectomy 
* not a breast cancer cell 
line 
  
Table 1. List of commonly used cell lines, the number of citations and their origin  
3.1 Breast cancer cell lines as models of primary tumors 
Using breast cancer cell lines clearly hold advantages over use of animal or human models. 
Beyond the ethical implications of animal or human use, the advantages to using cell lines 
include the ease of obtaining cell lines (can be purchased from commercial sources), the ease 
of harvesting large numbers of cells (can be grown in culture for long periods of time to 
accumulate the necessary concentration), and the ability to test an individual cell type 
without confounding parameters such as other cell types or local microenvironment (to 
date, no two cell lines can grown simultaneously in culture for extended periods). 
Conversely, much debate has circulated concerning the applicability of the data derived 
from isolated cell lines to the predicted outcomes in humans. One area that this debate has 
been most contentious has been regarding the importance of the immune system in cancer 
development. Clearly, the microenvironment and infiltrating immune cells contribute to 
development and progression of disease, therefore individual cells grown in isolation will 
lack the influence of other neighboring cells (Voskoglou-Nomikos et al., 2003). Genetic, 
epigenetic and cytotoxicity studies that focus on outcomes in breast cells clearly benefit from 
use of cell culture systems. The fundamental understanding of the underlying genetic or 
molecular pathways involved in breast cell growth and its response to cytotoxic agents are 
best understood in isolated cell culture systems (Voskoglou-Nomikos et al., 2003). 
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Fig. 1. The total number of publications per breast cancer cell line from 2000 through 2010. 
The most commonly used cell line is the ER+ MCF7 cell line, followed by ER - MDA-MB-
231 cell lines. Many other cell lines are in use, however the number of publications using 
these models is quite small. A. Total number of publications using breast cancer cell lines. 
B. Each breast cancer cell line as a percentage of the total breast cancer cell lines used per 
year. 
www.intechopen.com
 
Breast Cancer Cell Line Development and Authentication 
 
9 
 
Fig. 2. The total number of publications using breast cancer cell lines from 2000 through 
2010. Use of breast cancer cell lines has steadily been rising since 2000. 
 
 
Fig. 3. Number and percent of papers published using MDA-MB-435 cells from 2000 - 2010. 
The tumor type that gave rise to MDA-MB-435 cells has been controversial since 2000. In 
2004, STR profiling confirmed that MDA-MB-435 was not a breast cell line but rather has 
been contaminated with the M4 melanoma cell line. There has been a subsequent drop in the 
use and publication of these cells. Shown is the total number of papers published using 
MDA-MB-435 cells (green bars) and the percent of the total number of publications use 
MDA-MB-435 cells (blue circles). Arrow denotes when MDA-MB-435 were identified as 
M14 melanoma cells. 
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cell line 
year 
established 
origin 
ER/PR 
status 
BT-20 1958 primary tissue -/? 
SK-Br-3 1970 pleural effusion +/+ 
SW13 1971 ? ? 
MDA-MB-134-VI 1973 pleural effusion +/- 
MDA-MB-157 1973 pleural effusion ? 
MDA-MB-175-VII 1973 pleural effusion ? 
MDA-MB-231 1973 pleural effusion -/- 
MDA-MB-361 1973 brain metastasis ? 
MDA-MB-330 1973 pleural effusion ? 
MDA-MB-415 1973 pleural effusion ? 
MDA-MB-436 1973 pleural effusion ? 
MDA-MB-453 1973 pleural effusion -/- 
MDA-MB-468 1973 pleural effusion -/- 
MDA-MB-157 1974 pleural effusion ? 
MCF7 1974 primary tissue +/+ 
CAMA-1 1975 pleural effusion ? 
SW527 1977 ? ? 
Hs578Bst 1977 non-tumorigenic breast tissue -/- 
Hs578T 1977 primary tissue -/- 
ZR-75-1 1978 ascites +/+ 
ZR-75-30 1978 ascites ? 
BT483 1978 primary tissue ? 
DU4475 1979 primary tissue ? 
T47D 1979 pleural effusion +/+ 
MCF10A 1984 non-tumorigenic breast tissue -/- 
MCF10F 1984 non-tumorigenic breast tissue -/- 
MCF10-2A 1984 non-tumorigenic breast tissue -/- 
184A1 1985 normal mammoplasty (transformed) ? 
184B5 1985 normal mammoplasty (transformed) ? 
UACC-812 1986 primary tissue -/- 
UACC-893 1987 primary tissue -/- 
HCC38 1992 primary tissue -/- 
HCC70 1992 primary tissue -/- 
HCC202 1992 primary tissue -/- 
HCC1008 1994 lymph node -/- 
HCC1143 1994 primary tissue -/- 
HCC1187 1994 primary tissue ?/- 
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cell line 
year 
established 
origin 
ER/PR 
status 
HCC1395 1994 primary tissue -/- 
HCC1419 1994 primary tissue -/- 
HCC1428 1995 pleural effusion ? 
HCC1500 1995 primary tissue +/+ 
HCC1569 1995 primary tissue -/- 
HCC1806 1995 primary tissue -/- 
HCC1937 1995 primary tissue -/- 
HCC1954 1995 primary tissue +/+ 
HCC2157 1995 primary tissue -/+ 
HCC2158 1996 primary tissue -/? 
HCC1599 1998 primary tissue -/- 
AU565 1998 pleural effusion ? 
Table 2. Commercially available cell lines, their establishment date, and hormonal receptor 
status 
Debate has also centered on whether cell lines grown in culture maintain the same 
genotypic/phenotypic changes that are detected in the primary tissues from which they 
are derived. Characterization of breast cancer cell lines has been ongoing since their 
establishment in 1958. In general, breast cancer cell lines are representative models of the 
primary breast tumors they are derived from (Kao et al., 2009). Initial characterization 
including karyotyping and comparative genomic hybridization (CGH) demonstrate that, 
when created and propagated in culture, cell lines maintain the same mutations and 
chromosomal abnormalities as their primary tumor samples (Lacroix and Laclercq, 2004). 
While new mutations and chromosomal instability develop in cultured cell lines, overall 
the genotype remains generally consistent between primary cells and cell lines (Lacroix 
and Laclercq, 2004). Due to differences in the in vitro environment, lack of surrounding 
naturally occurring microenvironment, and selection pressures, differentiation in culture 
can occur (Kao et al., 2009; Lacroix and Laclercq, 2004; Voskoglou-Nomikos et al., 2003). 
Because cancer cells are inherently unstable, differences between same cell line grown in 
different labs under different environments, even if the growth conditions are the same, 
are evident (Lacroix and Laclercq, 2004; Osborne et al., 1987). This impacts 
experimentation as data derived from one lab may not be reproducible in another lab, 
even is using the same cell line. Caution must be taken when relying on one or two cell 
lines to draw conclusions. 
Use of more modern molecular techniques to characterize cell lines has revealed that while 
differences between primary cells and cell lines do exist. These techniques do confirm, 
however, that cell lines maintain the molecular distinction found the primary tumors. Gene 
expression changes detected in primary tumors are not dramatically different to those found 
in culture systems, even when cultures are grown directly on plastic in 2D cultures or in 
reconstituted 3D cultures (Vargo-Gogola and Rosen, 2007). Direct comparison of primary 
tissue to cultured cells revealed “close similarities” between molecular profiles (Dairkee et 
al., 2004). Indeed, even epigenetic changes found in primary cancers are similarly detected 
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in cell lines (Lacroix and Laclercq, 2004). This suggests that cell lines are an appropriate 
model of primary disease and, depending on the research focus, cell lines will faithfully 
reflect the processes of primary tissues. 
Since cell lines generally remain faithful in terms of the molecular and genetic profiles of the 
primary tumor from which they are derived, it is critical to consider the correct model 
system. While ER/PR status of primary tumors leans predominantly toward ER+ expression 
(55-60%), most breast cancer cell lines have been derived from ER - tumors or pleural 
effusions (McGuire et al., 1978)(Table 2). Therefore it is of utmost importance to select the 
proper model to answer the experimental question. A detailed analysis of the applicability 
of cell lines to accurately model primary breast tumors revealed that overall breast cancer 
cell lines as a whole do model primary tumors, however on an individual basis, one specific 
cell line does not accurately mirror a primary breast tumor, even with the same gene 
expression profile. Since variability in cell lines exist, it is generally thought that to more 
accurately predict outcomes in primary tissue, a panel of breast cancer cell lines rather than 
just 1 or 2 individual lines should be tested. Using panels more accurately reflects primary 
breast tumors and will help translate findings from in vitro studies to in vivo therapeutic 
options (Dairkee et al., 2004). 
Microarray analysis clearly defined primary breast tumors and breast cancer cell lines at the 
genetic level. Perou and others have conducted detailed studies using microarray platforms 
and determined a molecular signature of gene expression changes found in primary breast 
cancer tumors (Alizadeh et al., 2001; Perou et al., 1999b; Perou et al., 2000b; Ross et al., 2000; 
Sorlie et al., 2001). These signatures are used to understand the molecular basis of breast 
cancer and to define different subtypes of cancer that occur naturally in humans. It was also 
developed as a diagnostic tool to detect breast cancer tumors earlier and to facilitate proper 
treatment based on a gene signature. Based on these studies, 5 molecular signatures and 
types of primary breast tumors have been identified. These are luminal A, luminal B, basal-
like, HER2+, and normal-like profiles (Perou et al., 1999a; Perou et al., 2000a; Ross et al., 
2000; Sorlie et al., 2001). Prior to establishment of these molecular signatures, diagnosis was 
determined by receptor expression status, i.e. ER/PR/HER2, and treatment regimes 
assigned accordingly. Using this molecular approach, luminal A and luminal B tend to also 
be ER + expressing tumors, basal-like encompasses ER - tumors, HER2+ incorporate those 
HER2+ expressing tumors, and normal-like have similar expression patterns to non-
cancerous cells (Perou et al., 1999a; Perou et al., 2000a; Ross et al., 2000; Sorlie et al., 2001). 
Such molecular characterization will lead to providing more personalized therapy to 
patients. Efficacy of drugs in different subtypes will be easily determined and accurately 
assigned to patients expressing a similar molecular profile. While such personalized 
medicine may be still in the future, some current breast cancer treatment options that exist 
today are based on the molecular profile of the tumor. For example, tumors expressing the 
estrogen receptor are treated with selective estrogen receptor modulator (SERM) or other 
similar anti-estrogen compound whereas tumors lacking ER do not receive the same 
therapy. Similarly, HER2+ tumors are susceptible to trastuzumab because of HER2 
expression. In the future as molecular characterization improves and new 
chemotherapeutics are developed, more personalized options will be available. 
Do cell lines reflect the molecular signature of primary tumors? In a direct comparison of the 
molecular profiles from cell lines and primary tumors, Kao et. al. found that instead of the 5 
breast cancer subtypes identified in primary breast tumors, cell lines can be divided into 
three main groups, luminal, basal A, or basal B phenotypes (Kao et al., 2009). Luminal cells 
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contained all ER + cell lines, both Basal A and B consisted of all ER - cell lines. HER2+ cell 
lines were grouped into the luminal. Basal A contained the HCC cells and BRCA1 mutant 
cells, whereas basal B genotype contained non-tumorigenic lines including MCF10A cells 
(Kao et al., 2009). This highlights that breast cancer cell lines are a model of disease.  
Cell lines are merely a model of breast disease that aim to provide clinical predictability of 
outcomes in humans. To directly test the applicability of breast cancer cell lines, xenograft 
cancer models, and mouse breast cancer models to clinical outcome, Voskoglou-Nomikos et. 
al. compared outcomes in vitro to those in xenograft models, to mouse models and phase II 
clinical trails (Voskoglou-Nomikos et al., 2003). In these comparisons, a general correlation 
between relative risk (predictive value of a drug in cell line) and the phase II human trial 
(tumor/control ratio) existed for in vitro cell lines. A general predictive value when using 
xenograft models to predict outcome to chemotherapy was detected, however this was 
dependent on the drug tested and the grade/type of tumor analyzed (Voskoglou-Nomikos 
et al., 2003). Overall, Vaskoglou-Nomikos et. al. concluded that cell lines and xenograft 
models were good predictors of clinical phase II trial outcomes, but are reliable predictors 
only when testing cytotoxic drugs and when using the correct model system. These models 
generally were not predictive of human outcomes when testing non-cytotoxic drugs 
(Voskoglou-Nomikos et al., 2003). Taken together, these studies emphasize the critical need 
to establish more breast cancer cell lines that model the heterogeneity of breast cancer and to 
employ many in vitro and xenograft model systems using multiple cell lines per experiment 
to reliably predict clinical outcome.  
4. Contamination 
Overt contamination of cell lines, such as bacterial, fungal or yeast infections, is readily 
detectable merely by altered appearance of the culture and can be rectified without 
impacting the quality or reproducibility of the data. Less overt contamination, such as 
mycoplasma and cell line cross-contamination, can occur undetected and can seriously 
jeopardize experimental findings. While it is well recognized that periodic testing for 
mycoplasma is a necessary requirement when using cell lines, cross-contamination with 
other cell lines is less recognized as a problem and therefore and cell authentication 
practices are not routine. 
Cell line cross-contamination is most evident in the case of MDA-MB-435 cells. When Ross 
et. al. published the molecular profiles of breast cancer cell lines in 2000, the MDA-MB-435 
cell line consistently fell outside the range of profiles of the other breast cancer cell lines and 
clustered with melanoma cell lines (Ross et al., 2000). This sparked great debate about the 
authenticity of the this line. Derived in 1976 from the pleural effusion of a 31 year old 
patient with metastatic adenocarcinoma of the breast, initial debate suggested that this was 
still a breast cancer cell line, but had been derived from a patient who may have also had 
undiagnosed melanoma (Cailleau et al., 1978). Data indicating that MDA-MB-435 cells 
expressed a mixture of both melanoma and epithelial markers fueled this debate, however 
the overwhelming belief was the these were indeed breast cancer cells (Chambers, 2009; 
Sellappan et al., 2004)(Figures 2 and 3). Indeed, early characterization of the cell line 
indicated that they were highly metastatic and secrete milk proteins, findings consistent 
with those of breast cancer cells (Howlett et al., 1994; Price, 1996; Price et al., 1990; Price and 
Zhang, 1990; Sellappan et al., 2004; Suzuki et al., 2006; Welch, 1997). Confusingly, MDA-MB-
435 cells also expressed the melanocyte markers tyrosinase, melan A and S100 (Ellison et al., 
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2002; Sellappan et al., 2004). Because of such conflicting results, these data just propagated 
the debate instead of satisfactorily squelching it as intended. MDA-MB-435 cells were still 
used and published as a breast cancer cell line (Figure 3). 
Finally in 2007, DNA fingerprinting, or short tandem repeat (STR) analysis, in conjunction 
with SNP analysis, cytogenetic analysis, and comparative genomic hybridization using the 
earliest stocks of MDA-MB-435 cells revealed that these cells were identical to the M14 
human melanoma cells and were melanoma rather than breast cancer cells (Garraway et al., 
2005)(Rae et al., 2007). Rae et. al., who conducted the analysis, concluded that at some point 
early in passage, MDA-MB-435 cells were contaminated with M14 melanoma cells which 
took over the colony, leading to the establishment of a M14 melanoma cell line rather than a 
breast cancer line (Rae et al., 2007). This change was never detected. Stocks were 
unknowingly mislabeled, marked as MDA-MB-435 cells and distributed. Still, after the 
molecular characterization was published, debate as to whether MDA-MB-435 were really 
M14 melanoma cells or if M14 were really MDA-MB-435 breast cell still existed (Chambers, 
2009). Ultimately, it was determined that MDA-MB-435 cells were really M14, based on the 
original 1974 publication that initially characterized the morphology, growth and 
tumorigenicity of MDA-MB-435 cells. In the original paper, MDA-MB-435 cells were 
reportedly non-tumorigenic in nude mice. After the initial creation in 1974, the MDA-MB-
435 cells were not extensively used for testing until the 1990s when Price et. al. used these 
cells. At this time, MDA-MB-435 cells were characterized as a tumorigenic cell line (Cailleau 
et al., 1978; Price, 1996; Price et al., 1990; Price and Zhang, 1990).  
While impossible to reconstruct that actually happened, this indirect evidence suggests that 
the MDA-MB-435 cells were contaminated with M14 melanoma cells and the original breast 
cancer cells died off. Subsequent frozen stocks were of the contaminating M14 cell lines, 
although they were labeled as MDA-MB-435 cells. No one was aware of this 
misidentification. Therefore, M14 cells were masquerading as MDA-MB-435 cells and used 
as a model of breast cancer until 2007. A total of 1803 PubMed indexed articles using MDA-
MB-435 cells were published over that period (Figure 3). Since 2007, however, the number of 
publications using MDA-MB-435 cells has diminished, indicating that it is generally 
accepted that these cells are clearly not breast cancer cells and therefore should not be used 
as such.  
4.1 Authentication 
Cell line cross-contamination is hardly a new problem in tissue culture studies, although 
it still remains largely ignored. When HeLa were the only human cell line and few 
scientists studied them, cross-contamination was not a concern(Buehring et al., 2004; 
Skloot, 2010). Now, it is estimated that 20 - 30% of all cell lines are inadvertently 
contaminated (Alston-Roberts et al., 2010; Buehring et al., 2004; Gartler, 1968; Rojas and 
Steinsapir, 1983). Gartler et. al, was the first to highlight the problem in 1967 at the Second 
Decennial Review Conference on Cell, Tissue and Organ culture (Gartler, 1968). He was 
the first to demonstrate that many cultures from many labs were contaminated with other 
cell lines, primarily by HeLa cells. This meant that a significant amount of research was 
incorrectly interpreted because it was conducted in a different cell line and therefore the 
data were false. His findings were largely ignored. Over the years, others, including 
MacLeod, Freshney, Nardone, Alston-R, Buehring and Capes-Davis, have also 
documented contamination with HeLa and other cell lines, including cross-species 
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contamination, however this issue has rarely been adequately addressed (Alston-Roberts 
et al., 2010; Bartallon et al., 2010; Buehring et al., 2004; Capes-Davis et al., 2010; Freshney, 
2008; MacLeod et al., 2008; MacLeod et al., 1999; SDO et al., 2010). Recent efforts have 
again been made to increase awareness of this problem and many calls for action have 
been published (Buehring et al., 2004; Capes-Davis et al., 2010; Freshney, 2008, 2010b; 
Lichter et al., 2010; MacLeod et al., 2008; MacLeod et al., 1999; SDO et al., 2010). A group 
of concerned scientists gathered and created the ATCC Standard Development 
Organization (ATCC SDO) to develop standards for cell authentication and with 
maintaining databases of STR profiles. 
Eliminating contamination has an easy solution. Cell line authentication using a 
standardized technique, Short Tandem Repeat Analysis (STR), can provide an unique 
DNA fingerprint of the cell line (Azari et al., 2007; Bartallon et al., 2010; Masters et al., 
2001; Nims et al., 2010; Parson et al., 2005). STR is inexpensive, standardized, and 
provides proven methodology to produce cell line identities that is reproducible between 
labs. An aliquot of DNA can be analyzed and compared with known STR profiles to 
authenticate the cell line. STR profiles for the most commonly used cell lines are freely 
available and STR services are available at many universities or companies. According to 
the standards developed by the ATCC-SDO, cells in active use should be authenticated by 
STR every 2 months (SDO et al., 2010). The ATCC-SDO also recommends that such 
documentation of authenticity be provided with grant applications and with manuscript 
submission. Many funding agencies and journals agree with this idea and suggest that 
scientists provide such documentation prior to acceptance of a manuscript, however at 
this time, this is merely a recommendation. 
5. Future directions 
Use of breast cancer cell lines as models of breast disease will not diminish in the near 
future. These cell lines are an excellent resource to test novel hypotheses and to gain 
greater understanding about how cells work and how breast cancer can be treated. On the 
whole, the established cell lines are a good model for disease, however additional cell 
lines should be created. The addition on new lines, especially those derived from various 
forms of breast cancer will only strengthen the data gleaned from them. Likewise, cell 
authentication should become a routine part of experimental procedures. By periodically 
ensuring the cell lines being tested are truly the correct lines will eliminate the generation 
and publication of false data. Authentication will save money and potentially careers if 
done of a routine basis. 
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